An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
NCT06590480 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-12-18
Summary
The purpose of this EAP is to provide expanded access (i.e., before marketing authorization) to vusolimogene oderparepvec (VO; herein referred to as VO) plus standard-of-care (SOC), nivolumab, for eligible patients diagnosed with advanced melanoma, who, in their treating physician's opinion, could benefit from this treatment.
Conditions
Interventions
- BIOLOGICAL
-
RP1
Genetically modified Herpes Simplex Type 1 Virus
- BIOLOGICAL
-
Anti-PD-1 Monoclonal Antibody
Sponsors & Collaborators
-
Replimune Inc.
lead INDUSTRY
Principal Investigators
-
Tom Hash, MD · Replimune Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
NCT07040436 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Expanded Access Program With Nivolumab to Treat Melanoma
NCT02142218 ·Status: NO_LONGER_AVAILABLE
-
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
NCT04526730 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
NCT07091695 ·Status: COMPLETED
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT06295159 ·Status: RECRUITING ·Phase: PHASE2
-
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
NCT02186249 ·Status: NO_LONGER_AVAILABLE
-
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT05912244 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SBRT as a Vaccination for Metastatic Melanoma
NCT04042506 ·Status: WITHDRAWN ·Phase: PHASE2
-
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411 ·Status: RECRUITING
-
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
NCT03732560 ·Status: COMPLETED
-
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
NCT02083484 ·Status: NO_LONGER_AVAILABLE
-
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
NCT04698187 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
NCT03528408 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
NCT05418972 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
PVSRIPO in Combination With Nivolumab in Melanoma
NCT04125719 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT05704647 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
NCT05297565 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
NCT03259425 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant and Adjuvant Checkpoint Blockade
NCT02519322 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
NCT03084640 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
NCT04410445 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
NCT05665595 ·Status: COMPLETED ·Phase: PHASE3